| News
Basel is artificial intelligence hub
03.09.2019
The canton of Basel-Stadt is one of the three largest Swiss technology clusters for advanced digitalization technologies, as the new Digitalization Atlas has revealed. It is especially strong in artificial intelligence, with Roche, in particular, filing many patents in this area.

Digitalization Atlas of Switzerland for the technology Artificial Intelligence (Image: EconSight)
The economic research and consulting company EconSight has published its latest Digitalization Atlas. In this, it examines the patent activities of companies in advanced digitalization technologies across the various regions of Switzerland, with the aim of highlighting where local technology clusters can be found.
According to the results, the canton of Basel-Stadt is one of the three largest clusters for advanced digitalization technologies in Switzerland. With these technologies, EconSight means artificial intelligence, encryption, big data, cloud computing and virtual reality. In total, companies and research facilities in the canton of Basel-Stadt have filed 202 patents in these areas.
According to the Digitalization Atlas, the technological focus of Basel-Stadt is artificial intelligence, with 75 percent of advanced digitalization patents within this field. This trend is above all driven by the Basel-based pharma giant Roche. In Switzerland, Roche holds the highest number of patents in artificial intelligence (115 patents). Roche is followed by Zurich technology company ABB (108 patents) and, by quite some margin, Google’s parent company Alphabet (40 patents).
Roche remains the clear leader even when all five technology categories are taken into account. With 149 patents, the Group ranks third behind the Western Swiss company Kudelski (213 patents) and ABB (196 patents).
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
Noema Pharma raises 103 million Swiss francs from investors
Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....
Read MoreBasel still the most attractive small city for business in Europe
As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...
Read MoreAriceum Therapeutics establishes subsidiary in Basel
The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...
Read MoreRocketVax raises fresh capital
The Basel-based biotech startup RocketVax has successfully closed another financing round. This additional funding will primarily be used to further...
Read MoreClinerion is now part of Citeline
Clinerion has been integrated into New York-based company Citeline. Clinerion plans to expand its portfolio with Citeline’s complementary opportunities with...
Read MoreKUORI developing biodegradable plastics
The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...
Read MoreCell and gene therapies gain momentum in Basel
Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...
Read MoreBLKB expanding support for startups
BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...
Read MoreCombatting the rise of antimicrobial resistance
Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...
Read MoreAMR Action Fund invests in new antibiotics developed by BioVersys
The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...
Read More